Electron emission tomography (PET) technology is used to detect Tau protein deposition in the brain of AD patients in the clinic using specific PET probes that are able to bind to P-Tau in vivo in a conformation-dependent manner, such as the Tau PET probe 18F-T807. The gene discussed is MAPT; the disease is Alzheimer disease.